Sze Ting Lee Selected Research

Sze Ting Lee Research Topics

Disease

14	Neoplasms (Cancer) 03/2022 - 08/2012
8	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2011
6	Hypoxia (Hypoxemia) 01/2021 - 11/2007
5	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 04/2014
4	Prostatic Neoplasms (Prostate Cancer) 08/2012 - 01/2009
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 07/2018 - 10/2017
2	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 01/2020
2	Disease Progression 01/2021 - 01/2020
2	Renal Cell Carcinoma (Grawitz Tumor) 07/2018 - 01/2014
2	Carcinoma (Carcinomatosis) 11/2015 - 07/2012
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2022
1	Hematologic Neoplasms (Hematological Malignancy) 03/2022
1	Thyroid Neoplasms (Thyroid Cancer) 01/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Melanoma (Melanoma, Malignant) 01/2021
1	Brain Neoplasms (Brain Tumor) 01/2021
1	Ovarian Neoplasms (Ovarian Cancer) 01/2020
1	Necrosis 03/2018
1	Colonic Neoplasms (Colon Cancer) 04/2014
1	Squamous Cell Carcinoma of Head and Neck 11/2013
1	Head and Neck Neoplasms (Head and Neck Cancer) 11/2013
1	Carcinogenesis 10/2013
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2013
1	Urinary Bladder Neoplasms (Bladder Cancer) 07/2012
1	Malignant Mesothelioma 06/2011
1	Mesothelioma 06/2011

Drug/Important Bio-Agent (IBA)

6	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022 - 09/2012
4	fluoromisonidazoleIBA 01/2021 - 11/2007
3	ErbB Receptors (EGF Receptor)IBA 01/2021 - 10/2013
3	AntigensIBA 01/2021 - 07/2012
3	Biological ProductsIBA 07/2014 - 07/2012
2	Immunoconjugates (Immunoconjugate)IBA 03/2022 - 01/2021
2	Bevacizumab (Avastin)FDA Link 01/2021 - 11/2015
2	depatuxizumabIBA 01/2021 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2013
2	gallium Ga 68 dotatateIBA 07/2018 - 01/2018
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2018 - 11/2015
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2018 - 10/2017
2	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2018 - 10/2017
1	AntibodiesIBA 03/2022
1	Radioisotopes (Radionuclides)IBA 03/2022
1	EphrinsIBA 01/2022
1	Thyroglobulin FDA Link 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	depatuxizumab mafodotinIBA 01/2021
1	Zirconium-89IBA 01/2021
1	epidermal growth factor receptor VIIIIBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	tumor-associated antigen 72IBA 01/2020
1	Glycoproteins (Glycoprotein)IBA 01/2020
1	indium-111-octreotideIBA 07/2018
1	VimentinIBA 03/2018
1	MucinsIBA 03/2018
1	Indicators and Reagents (Reagents)IBA 03/2018
1	Octreotide (Sandostatin)FDA LinkGeneric 01/2018
1	Cetuximab (Erbitux)FDA Link 11/2015
1	Therapeutic UsesIBA 11/2015
1	Capecitabine (Xeloda)FDA Link 04/2014
1	Tyrosine Kinase InhibitorsIBA 10/2013
1	InterferonsIBA 10/2013
1	14-3-3 Proteins (14-3-3 Protein)IBA 10/2013
1	Monoclonal AntibodiesIBA 10/2013
1	Choline (Choline Chloride)IBA 08/2012
1	Glucose (Dextrose)FDA LinkGeneric 07/2012
1	Lutetium-177IBA 01/2009
1	Docetaxel (Taxotere)FDA Link 01/2009
1	Hu3S193 monoclonal antibodyIBA 01/2009
1	Oxygen (Dioxygen)IBA 11/2007

Therapy/Procedure

9	Therapeutics 03/2022 - 09/2012
8	Drug Therapy (Chemotherapy) 01/2021 - 01/2009
8	Radiotherapy 01/2020 - 06/2011
2	Precision Medicine 03/2022 - 10/2017
2	Immunotherapy 01/2021 - 01/2021
2	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2019 - 06/2011
2	Prostatectomy (Retropubic Prostatectomy) 08/2012 - 05/2011
1	Enteral Nutrition (Feeding, Tube) 01/2019
1	Conformal Radiotherapy 06/2011
1	Radioimmunotherapy 01/2009